
For Sarepta Therapeutics (NASDAQ: SRPT), 2025 has been nothing short of an unmitigated disaster. The firm owns the only Food and Drug Administration (FDA)-approved gene therapy for the treatment of Duchenne muscular dystrophy (DMD), known as ELEVIDYS. Since gaining approval in June 2023, Sarepta has generated over $1 billion in revenue from ELEVIDYS. However, that success has been massively overshadowed by key failures.
In 2025, multiple people treated with ELEVIDYS have died, causing shares to plunge. Overall, Sarepta shares are down by more than 85% in 2025, as of the Aug. 11 close. However, multiple Wall Street analysts seem to believe a huge recovery could be in store for Sarepta.